Core Viewpoint - INVO Fertility, Inc. will implement a 1-for-5 reverse stock split effective March 27, 2026, which will affect its issued and outstanding common stock as well as its authorized common stock [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 5 shares of common stock into 1 share, with fractional shares being rounded up to the next whole share for registered holders [2]. - Beneficial holders in street name will receive a cash payment for fractional shares, determined by their brokers [2]. - Post-split, the company will have approximately 1,615,419 shares of common stock issued and outstanding, and the authorized shares will be adjusted to 50,000,000 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [3]. - The company operates four fertility clinics in the U.S. and aims to provide a more natural and affordable experience through its intravaginal culture (IVC) procedure [3]. - The IVC procedure is positioned as a cost-effective alternative to traditional IVF, offering comparable results at a lower price [3].

Core Viewpoint - INVO Fertility, Inc. has adopted time-lapse incubation technology at its Wisconsin clinic, reflecting its commitment to high-quality patient care and innovative solutions in the fertility sector [1][3]. Group 1: Technology Adoption - The integration of time-lapse incubation technology enhances the tools available to embryology teams, aligning with the company's focus on quality and innovation in patient-centered fertility care [2][3]. - Time-lapse imaging provides detailed developmental information while embryos remain in a controlled environment, supporting informed clinical decisions [6]. Group 2: Patient Benefits - Patients benefit from advanced laboratory innovation without added complexity, receiving video records of their embryo's development, which increases engagement and understanding of the process [6]. - The use of proven, FDA-cleared technology reflects the company's focus on quality, safety, and clinical rigor, enhancing patient confidence in the treatment [6]. Group 3: Company Strategy - INVO Fertility's strategy includes expanding access to assisted reproductive technology (ART) through building, acquiring, and operating fertility clinics, including the INVO Centers [4]. - The company emphasizes responsible integration of advanced reproductive technologies that deliver meaningful value to patients and clinicians [3][4].

Core Viewpoint - INVO Fertility has joined the Progyny network, enhancing its access to employer-sponsored patients and expanding its market reach in Wisconsin and surrounding areas [1][2][4]. Group 1: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to advanced reproductive treatments through the establishment and operation of fertility clinics [1][7]. - The company operates four fertility clinics in the United States and is engaged in the sale and distribution of its proprietary INVOcell technology, which allows fertilization and early embryo development to occur in vivo [7]. Group 2: Partnership with Progyny - The partnership with Progyny significantly increases WFI's access to a broader patient base, providing in-network access to a comprehensive suite of reproductive services, including IVF and fertility preservation [2][3]. - Progyny serves approximately 7.2 million covered lives through over 600 employers, which enhances WFI's potential patient pool [2]. Group 3: Market Trends and Strategic Importance - Employer-sponsored fertility benefits are rapidly growing as companies seek to attract and retain talent, making alignment with leading fertility benefits managers crucial for organic growth [4][5]. - The partnership is viewed as a major milestone for INVO Fertility, supporting its strategy to scale its clinic platform and strengthen long-term financial performance [5][6].

Core Insights - INVO Fertility's Wisconsin Fertility Institute has joined the Progyny network, enhancing its market reach and access to employer-sponsored patients [1][2] Group 1: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to advanced reproductive treatments through the establishment and operation of fertility clinics [1][7] - The company operates four fertility clinics in the United States and is engaged in the sale and distribution of its proprietary INVOcell technology [7] Group 2: Market Expansion - Joining the Progyny network significantly increases WFI's addressable market within Wisconsin and surrounding regions, providing access to an estimated 7.2 million covered lives through over 600 employers [2][4] - Employer-sponsored fertility benefits are one of the fastest-growing segments in healthcare, as companies seek to attract and retain talent [5] Group 3: Service Offerings - Eligible patients now have in-network access to WFI's comprehensive suite of reproductive services, including diagnostic testing, in vitro fertilization (IVF), and fertility preservation [3][4] - Progyny's benefit design simplifies financial and administrative processes, reducing barriers to care and improving treatment utilization and outcomes [3] Group 4: Strategic Importance - Participation in the Progyny network enhances WFI's third-party payor mix and expands its services to a larger patient base [4] - The partnership with Progyny is viewed as a major milestone that supports INVO Fertility's broader strategy to scale its clinic platform and strengthen long-term financial performance [5][6]

Core Viewpoint - INVO Fertility, Inc. has successfully completed the acquisition of Family Beginnings, a respected fertility clinic, enhancing its growth strategy and expanding access to high-quality fertility care [1][6][7] Group 1: Acquisition Details - The acquisition of Family Beginnings was finalized in accordance with a definitive purchase agreement announced on December 17, 2025 [2] - INVO acquired the non-clinical assets of Family Beginnings for a total purchase price of $760,000, which includes cash and preferred stock [6] - Family Beginnings generated approximately $1 million in revenue and $0.2 million in net income for the nine months ending September 30, 2025, representing about 18% of INVO's clinic revenue for the same period [5] Group 2: Company Strategy and Operations - The acquisition aligns with INVO's strategy to expand its network of fertility care centers and improve patient access to advanced reproductive care [6][7] - Family Beginnings is known for its patient-first approach and continuity of care, which complements INVO's mission to provide compassionate fertility care [4] - The existing medical leadership and care teams at Family Beginnings will remain in place, ensuring continuity while benefiting from INVO's resources and technology [5] Group 3: Company Background - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) and operates four fertility clinics in the United States [8] - The company emphasizes the INVOcell medical device, which allows fertilization and early embryo development to occur in vivo, offering a more intimate and affordable experience compared to traditional IVF [9]

Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]

Core Viewpoint - INVO Fertility, Inc. is positioned for growth with a strengthened fundamental position, focusing on operational progress, disciplined capital management, and a clear growth strategy [3][4][21]. Operational Progress - The company has three operational fertility clinics generating positive cash flow, marking a critical milestone in achieving profitability at the clinic level [5]. - INVO Fertility is nearing the acquisition of a fourth clinic in Indianapolis, which will diversify revenue and enhance earnings power [6]. Financial Performance - The combined pro forma annualized revenue run rate from all clinics is approximately $9 million, providing a strong baseline for growth [7]. - The company has simplified and strengthened its capital structure, with recent financing issued at a fixed price of $1.59, enhancing clarity and alignment for shareholders [16][17]. Growth Strategy - Organic growth is a key component of the strategy, focusing on increasing patient volumes and optimizing treatment pathways [8][9]. - Acquisitions are a cornerstone of growth, with a robust pipeline of potential targets under evaluation, emphasizing clinics with strong reputations and operational improvement opportunities [10][11][12]. Market Environment - Recent executive actions support federal access to IVF and fertility treatments, potentially increasing patient demand and utilization of fertility services [13]. - The company anticipates strong growth in 2026, driven by acquisitions and organic expansion, addressing the rising global infertility rates and limited access to affordable services [14][15]. Future Outlook - INVO Fertility is positioned for a higher-growth phase with a stabilized operational base and a strong balance sheet, aiming to build a scalable platform for sustained growth [19][21].

Core Viewpoint - INVO Fertility Inc. has entered into a warrant inducement agreement with an investor for the immediate exercise of certain outstanding warrants, resulting in expected gross proceeds of approximately $7.5 million [1][3]. Group 1: Warrant Inducement Agreement - The investor has agreed to a reduced exercise price of the December 2025 Warrants to $1.59, allowing the purchase of 4,733,728 shares of common stock [1]. - In exchange for the immediate exercise of existing warrants, the company will issue unregistered warrants to purchase an additional 9,467,456 shares at the same exercise price of $1.59, subject to shareholder approval [3]. - The closing of the warrant exercise transactions is anticipated to occur on or about January 30, 2026, pending customary closing conditions [4]. Group 2: Financial Advisory and Compliance - Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction [2]. - The New Warrants are being offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933, and have not been registered under the Act [5]. Group 3: Company Overview - INVO Fertility is a healthcare services company focused on expanding access to assisted reproductive technology (ART) care, operating fertility clinics and offering the INVOcell medical device [7]. - The company has two operational INVO Centers in the U.S. and one IVF clinic, and continues to sell and distribute INVOcell to third-party clinics [7]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more intimate and affordable experience compared to traditional IVF [7].

Company Overview - INVO Fertility, Inc. is a healthcare fertility company focused on establishing, acquiring, and operating fertility clinics and related technologies [3] - The company operates two INVO Centers and one IVF clinic in the United States, and it sells the INVOcell medical device to third-party fertility clinics [3] - INVOcell is a proprietary medical device that allows fertilization and early embryo development to occur in vivo within the woman's body, offering a more intimate and affordable experience compared to traditional ART treatments [3] Upcoming Event - INVO Fertility will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026, at 3:00 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2]

Core Viewpoint - INVO Fertility, Inc. has announced a realignment of its executive leadership team to better support its growth strategy focused on the establishment and acquisition of fertility clinics and related businesses [1][3]. Leadership Changes - Terah Krigsvold has been appointed as the new Chief Financial Officer (CFO), replacing Andrea Goren, who will now serve as Chief Business Officer and CEO of INVO Centers LLC, a subsidiary focused on fertility clinics [2][3]. - The leadership changes are intended to enhance the company's ability to execute its growth plan and achieve profitability [3]. Company Strategy - INVO Fertility is dedicated to expanding access to assisted reproductive technology (ART) and focuses on building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [4]. - The company currently operates two INVO Centers and one IVF clinic in the United States and is involved in the sale and distribution of the INVOcell device to third-party clinics [4]. Product Offering - The INVOcell device allows fertilization and early embryo development to occur in vivo within the woman's body, providing a more intimate and affordable experience compared to traditional ART treatments [4]. - The IVC procedure enabled by INVOcell is believed to deliver comparable results to traditional IVF at a significantly lower cost and is more effective than intrauterine insemination [4].